Verastem, Inc.

( )
VSTM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. -0.94%240.321.3%$790.96m
IMMUImmunomedics, Inc. 0.15%85.3011.0%$689.14m
MRNAModerna, Inc. -2.96%65.170.0%$688.38m
GILDGilead Sciences, Inc. -1.33%62.251.0%$574.97m
NVAXNovavax, Inc. 0.86%102.4496.5%$560.41m
ILMNIllumina, Inc. 4.88%286.313.5%$502.92m
REGNRegeneron Pharmaceuticals, Inc. -1.37%557.462.7%$425.08m
BIIBBiogen, Inc. -0.79%270.041.6%$333.15m
VRTXVertex Pharmaceuticals, Inc. -0.26%263.131.9%$328.25m
ALXNAlexion Pharmaceuticals, Inc. -0.37%112.022.0%$278.23m
SRNESorrento Therapeutics, Inc. -4.27%9.191.5%$246.35m
EXASEXACT Sciences Corp. 26.85%94.3120.7%$232.04m
SGENSeattle Genetics, Inc. 0.09%179.436.0%$203.87m
VXRTVaxart, Inc. -4.17%6.890.0%$198.58m
MNTAMomenta Pharmaceuticals, Inc. 0.19%52.393.0%$197.85m

Company Profile

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRAâ„¢ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.